On the other side of the world.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Actually, that's not correct. There would still need to be a second transaction recorded at 2000 as a sell or neutral. That's because OTC and NASDAQ trades are In 2 parts: the liquidation (sale) and the acquisition (buy, but not recorded as a buy unless acquired at the ask). The second part would need to be recorded if actually at the bottom of a 2k share purchase. There would be 2 2k share trades with in seconds of the each time stamp.
Do you have any evidence at all that Aspire is selling shares 6 digits deep past the decimal point? Any evidence? Anything?
Is striking again? Up 1.5 after the current pattern of dipping at the open (like Ginger in Fred's arms) and rising beautifully.
This little rattler is ready to strike!
Difference between slander and libel:
Slander=a kinda lizad - da slander lives ina water
Libel=might gonna - libel ta punchya ina noze
Important repost for those who missed it:
Other lame metaphors not involving trains, explosions or rockets:
This little horse gonna fly.
This elephant gonna stomp some shorts.
This cheese gonna pizza.
This cake gonna rise (but don't slam the door).
This y = 2(x-3)squared +4 gonna go parabolic positive.
This pupa gonna metamorphosis.
This MLK gonna climb the mountain and see the promised land.
These IPIX shorts gonna think they spilled flaming shots.
This little star gonna supernova. No, wait, that's an explosion metaphor. OK, I'm done.
Though open through midday was as predicted, the trading into the afternoon was a little stronger than expected. Though it continued the rounding pattern from yesterday, it's now broken that pattern on higher volume going into the close. Very good buying as we enter the second half of the week on a day I associate with weak trading and profit taking. The current rally has legs.
I'm beginning to see the game as a magic act where the audience follows an illusion from the pledge, to the turn and finally the reveal in the 3rd act, the prestige. The reveal is something unthinkable, the payoff for the turn in the illusion. Currently, bears have been in control of the narrative, but in the coming 3rd act will be something astonishing to most, but totally expected by those few watching closely, yet not so close to be taken in by the (until recently) narrative. The twist is coming for those on the sidelines.
Midweek of a two day rally going into essentially a 4 day weekend. We should see some weakness today closing even to off a few pennies. Next week is a holiday week so I expect some MM and FUD shenanigans on lower volume, but not much because the following week is the first big reveal. Short players will be looking to cover anything not covered so they are unlikely to double-down this time.
Keep up the buying pressure by buying into any weakness. Wack the ask. Make them move those fake walls.
You do know that to paint a red hammer, the price has to at least descend to the open and the bid has to drop below the opening price for that paint? Even at the time you posted that nonsense there was no movement correcting toward the open. And, no, before it's posted, the close was not painted. There was enough buying volume to lift the final trades from .88 to .90.
It's lightening speed compared to most other cancer trials. Average time for a Phase 2 trial is 16 months. This trial's estimated completion, including final data, is 11 months.
Other lame metaphors not involving trains, explosions or rockets:
This little horse gonna fly.
This elephant gonna stomp some shorts.
This cheese gonna pizza.
This cake gonna rise (but don't slam the door).
This y = 2(x-3)squared +4 gonna go parabolic positive.
This pupa gonna metamorphosis.
This MLK gonna climb the mountain and see the promised land.
These CTIX shorts gonna think they spilled flaming shots.
This little star gonna supernova. No, wait, that's an explosion metaphor. OK, I'm done.
Desperation at its best as MMs resort to "best-bid" fill the bid walk down now using 6 digits to the right of the decimal point. Scumbags.
Yet it bounced off 88 and went back over 90. Yeah lots of flipper selling, but also a lot more buying creating nice support above 85, well above 85.
Well, CDEL (and others) tried to cap again by going "best bid" fractional posting, again, but failed when volume picked up. So, for 10 minutes "selling" was correct if you count the walk-down by filling bids, and not allowing trades at ask.
4 Phase 2 trials across 3 platforms and 4 diseases/indications. However, it's unlikely that K phase 2 will complete in 2017. But who needs it in 2017? We have 3 phase 2s for 3 >billion dollar drugs.
...amazing period with four Phase 2 trials prepping to read out in 2H17...
Agree, there will be small corrections for each leg on the way up. These will be hard to time (out and back in) until a pattern is established. Even then, news cycles will override patterns thus breaking patterns, in particular the really good news we anticipate. But the best and most reliable trading opportunities will be following larger moves, roughly the numbers you outline.
Yes, left out for a reason. Those words are reserved for the data release at the coming July 13 thing. How the market plays the presentation is yet to be determined, but there should be more anticipation buying between now and then.
The FDA does not comment. Anyone in the biopharma trading and/or investing arena has to know this. The FDA comments are limited to feedback on trial design, guidance, and proposals such as INDAs and NDAs.
Oh, bullshit! That move yesterday was MM covering last week's open positions, retail anticipation buying on great news, and short covering. After 10:00 the continuing climb showed no signs of large Aspire selling and every sign of unrelenting short covering, and especially those new short positions from the last 2 weeks.
Too close to the goal line forcing retail to buy in. But, that 100k at .80 had the smell of short covering all over it. The 2 week 80k increase in short positions had to be around and mostly under .80. Expect short traders to begin ramping up reload and FUD as the intraday volume slows. Continued buying, even small lots, will crush them this time, and force them to cover rather than absorb low volume buying. Anyone trying to flip the dime will lose this time. Traders trying to time the $1 pullback will wind up chasing 1.10+. At least that's how I'm playing this current leg up. I can't lose even if I'm wrong. Too close to the goal line.
Yep, 3 arms:
Placebo
300mg (150mg BID)
400mg (200mg BID)
https://clinicaltrials.gov/ct2/show/NCT02949388?term=cellceutix&rank=5
No 200mg arm unless someone misreads 200mg BID as the arm. But, why would anyone do that?
IMO, the company will use a P partnership to leverage a B partnership or vice versa. The company is not currently structured to quickly advance drugs to market under accelerated conditions. Both drugs need partnerships. An infusion from BP of 10s of millions of dollars changes the partnership paradigm for the remaining drug and all indications. I think a B partnership is more quickly setting up.
There are policies and procedures that would allow a direct to Phase 4, but the bar is very high, especially for safety data. Though, they may have enough data for a very large and well connected BP partner to convince the FDA based on unmet need and ability to rapidly advance an NDA to market. The most likely outcome, however, is a smaller Phase 3 pivotal trial with an approval agreement.
Exactly! Now that IPIX has demonstrated nearly no systemic Brilacidin absorption the follow up trials will come as ne'er as optical rinse rules which are far less stringent. It will be interesting to see how the next OM and UP trials are designed and powered considering they fall under unmet need as well as topical drugs.
Since the CEO and other officers have repeatedly made clear that licensing will follow a fuller characterization across indications and better understanding of the MOA, I don't see what the point is in driving home a lack of Phase 3 trials when the business plan does not include IPIX alone taking drugs to market. Phase 3 will either follow funding from a license or will be carried out by a licensee. All current trials clearly are designed with licensing goals in mind.
If one actually looked at a chart, instead of pulling numbers out of one's (hat),one would find the current price up for the week over last week. Not down 10% but up 2%.
Closed green. All that trash talk about down again only to close green. Closings all week, so far, have been even or green. Yet, you'd think it was sliding 3% everyday according to the most shrill and mocking voices. Go figure.
You are still misusing charts and TA. Up is down, as usual. Bottom formation and sideways for the 3rd day is not "bid getting pounded." RSI is oversold and other indicators showing bottom and rising.
Three days sideways, looks like buying pressure is coming back in. On the road this week while back in the USA, so intermittent posting. Sideways, continuing sideways with increased pressure going into the weekend. Happy summer to all.
It was a proof of concept trial, not statistically powered. 13 of 28 is 46.42%, rounded down to 46%. Or, ~46%. Working the other way, 46% of 28 is 12.88, rounded up to 13 patients. PoC trials demonstrate trend and are not intended to present more precise results as those for 10 times the patients at a single optimized dose.
One does not say one has full faith and support while talking about possible failings of same. It's a dictionary contradiction. Especially true when evidence supports no failures past, present, or future.
Absolutely not true! Capital G does not have your full faith and confidence. If he did you would not couch your comments in such conditional terms.
There is very limited empirical evidence that Prurisol will topple Otezla. I won't be surprised either way. Capital G has my full faith and confidence.
Whether or not there is something going on behind the scenes is immaterial. Anything done requires some SEC participation to be effective. The SEC's enforcement division just got its funding chopped (a freer and less regulated market), so don't expect much from them. The only thing left for Leo, et al to do is put together a law suit for damages based on....what exactly?
It has nothing to do with Mako's control over the stock price. It has to do with hedge fund market makers using their power to fill buys without intention of covering except at lower prices. It has to do with shifting to fractional trades of 5 to 6 digits to the right of the decimal point which allows them to walk down bid and ask based on so-called best bid practices by ignoring higher non fractional bids because they are not "best bids." Mako is nothing more than the excuse for bear raids.
What nonsense. It was a green, spinning top. The hammer was on Friday and it was a bullish inverted hammer confirmed by yesterday's close. Not a strong signal, so needs today to be green and above the 50ma, but definitely not bearish.
Swing traders shaving 5-10% on each small run up while trash-talking after the shave. I'm pretty sure (read certain) you know this. Some are building core positions and others are here for the clipping cycles. The latter will disappear after the first deal and run to $10, at which point they will already be long gone.
Yes, any reasonable offer. I'm sure, in fact certain, he is using some of the same valuation tools I've posted here to arrive at a range of acceptable offers based on the current and near future pipeline and milestones. I'm also sure (read certain) that he has worked out a dozen scenarios up to and including a BP acquisition. His expectations are not "million in one" pricing, as one poster put it, his valuations be are based on a dozen factors including (but not limited to) potential market(s), stage of development, risk assessment, cost to approval, recent similar agreements, specific milestones remaining to market, and upfront and milestone payments verses backend payments and royalties. He has a specific number in mind for each indication, each platform and all of it. Anyone lowballing for it all will get nothing. Anyone hoping to get one indication should not be firm in a lowball first offer for that license.
Actually, no it won't be "trial and error." There will be a small patient (not tiny patients, but small number, say 10) bridge study. Using mouse studies, human MOA, and PK/PD from the current OC phase 2, the study should examine a small range escalation, much like the current OC. But, none of that will matter to IPIX because the potential partner who wanted to see a more clearly defined PK/PD and MOA will do all that.
All this will be trial and error and will add to overall timeline.
Yes, both open and naked CTIX positions have to be covered by Tuesday close. Open positions are just part of the normal daily trading. Naked positions are open positions with no intention to cover or borrow shares. During a cusip and name change, there is usually adequate time beginning with the notice of change for covering both if the naked position is negligible. There have been cases I've seen that resulted in large runs, but that requires a patient wait of all 3 days to see how things play out.
All I said was naked and open positions have until Tuesday close to cover those positions from CTIX days. Just stating the rules. Nothing more.